Better Breathing
Spring Edition 2025
A HERO IN MOTION Kath Cross' inspirational story
CALLUM'S
HALF MARATHON RUN FOR ASTHMA
'I LOVE YOU MUMMY...
23-year-old goalkeeper’s fundraising challenge for lung health
PLEASE DON'T DIE TODAY' A mother’s fight against asthma
ICE IDENTIFI
BUDESONI DE
$
$
50 mcg
$
100 mcg Accuhaler®
$
250 mcg
100 mcg
Spiromax®
$
$
$
$
200/6 400/12* Dry powder inhaler
*Symbicort 400/12
Vannair®
$
100/6
200/6
and DuoResp Note: Symbicort Aerosol inhaler Spiromax 400/12 100/6, 200/6 only funded and DuoResp Vannair 100/6 if no more than Spiromax 200/6 and 200/6 is are currently 2 doses per day approved for approved for maintenance Anti-Inflammatory use, but its use Reliever (AIR) in AIR therapy therapy. is an unapproved indication.
Long-Actin g Beta2 Agonists
SALMETERO L
Serevent®
FORMOTER OL (eformotero l)
50 mcg Accuhaler®
M + OLODATER OL
6 mcg Turbuhaler®
UMECLIDIN IUM + VILANTERO L
Anoro Ellipta®
$
150 mcg 300 mcg Breezhaler
62.5 mcg/25 mcg Dry powder
®
GLYCOPYR RONIUM + INDACATER
OL Ultibro® Breezhale r®
$
2.5 mcg/2.5 mcg Fine mist inhaler
$ 50
free to those Contact Manatū Hauora Ministry who need them on a Practitioners Everyone should of Health for Supply Order have an action an order form (PSO). on 0800 353 plan. Find a range of management 2425. plans at asthmafound ation.org.nz
$
Funded by
Low carbon 1. Wurzel DF,
Not funded
endorseme nt
footprint1
Montgomery
BD, Anderson
Seretide®
$
$
Partially funded
Funded by
High carbon N et al. Environmental
Special Authority
footprint1
impact of inhaled
medicines: A
(ultrafine particle)
$
$
$
$
mcg 250 mcg Aerosol inhalers
and Qvar® are
not dose equivalent
+ SALMETERO L
50 mcg 100 mcg and are not
interchangeable.
FLUTICASO NE furoate + VILANTERO L
Breo Ellipta®
$
$
$
50/25
125/25 250/25 Aerosol inhaler
$
$
$
100/50*
250/50* Accuhaler®
$
100/25
*100/50 and 250/50 accuhaler only funded if no more than 2 doses per day
Long-Actin g Muscarinic
TIOTROPIU M
Spiriva®
Spiriva Respimat®
$
mcg/110 mcg Funded via inhaler Special Authority: stabilised on Breezhaler® LAMA + a from switching LAMA and the prescriber LABA inhaler is subsidised combination to a combination product.considers that the patient only for patients who have been ICS and LABA. would Not subsidised if patient is also receive additional benefit receiving treatment Spacers are with a available
$
propionate
INDACATER OL
Onbrez Breezhale r®
$
Combination Long-Actin g Muscarinic + Long-Actin Antagonists g Beta2 Agonists (LAMA) (LABA) TIOTROPIU
Spiolto Respimat®
$ 50 mcg 100 Note: Beclazone®
Combination Inhaled Corticoste + Long-Actin g Beta2 Agonistsroids (ICS) FLUTICASO (LABA) NE
$
25 mcg Aerosol inhaler
BECLOMET HASONE dipropionat e Qvar®
$ 400 mcg
Dry powder
200/25 inhaler
(LABA)
Oxis®
$
RELIEVER
$
200/6 400/12* Turbuhaler®
Thoracic Society
$ 18 mcg Handihaler®
Antagonists (LAMA)
UMECLIDIN IUM
Incruse Ellipta®
$ 2.5 mcg Fine mist inhaler
GLYCOPYR RONIUM
Seebri® Breezhaler®
$
$
62.5 mcg
Dry powder Funded by 50 mcg endorsement: inhaler having COPD LAMA inhaler Breezhaler® using spirometry is subsidised (i.e. COPD documented only for patients if spirometry is possible, who have been as indication Not subsidised diagnosed as on prescription). and the prescription if patient is also is endorsed receiving treatment accordingly with another susidised LAMA.
Combination Inhaled Corticoste Antagonist roids (LAMA) + Long-Actin(ICS) + Long-Actin g Beta2 Agonist g Muscarinic FLUTICASO (LABA) NE furoate UMECLIDIN + IUM + VILANTERO L Trelegy
Ellipta®
BUDESONI DE + GLYCOPYR RONIUM + FORMOTER OL
Breztri Aerospher e®
$ 100 mcg/62.5 mcg/25 mcg Dry powder inhaler
$ 160 mcg/7.2
Funded via mcg/5 Special Authority: Aerosol inhaler mcg with a diagnosis ICS + LAMA + LABA ‘triple acceptable resultsof COPD confirmed by therapy’ inhaler spirometry, are not possible and meets the and the patient or spirometry has been is subsidised only for patients attempted and is currently on • Patient has following clinical criteria: technically an ICS/LABA a • Patient has COPD Assessment Test or a LAMA/LABA, (CAT) had 2 or more • Patient has exacerbations score greater than 10, had one exacerbation or in the previous • Patient has 12 months, requiring hospitalisation had an eosinophil or or the patient count greater in the previous is 12 months, the clinical criteriacurrently receiving multiple than or equal to 0.3 or x 10^9 cells/L inhaler above prior in the previous to starting multiple triple therapy (ICS/LAMA/LAB 12 months inhaler triple A) and met at therapy. Funding information least one of updated as of 1 June 2025.
Visit www.ph armac.govt.nz of Australia and New Zealand
position statement.
Respirology,
2025.
RELIEVERS
100 mcg/20 mcg Aerosol inhaler
Beclazone®
$ 200 mcg Turbuhaler®
+ PREVEN
BUDESONI DE + FORMOTER OL DuoResp
TER
Combination Inhaled Corticoste + Long-Actin g Beta2 Agonistsroids (ICS) (LABA)
$
$
20 mcg Aerosol inhaler
Inhaled Corticoste roids (ICS)
(FOR COPD)
$
HFA®
$
250 mcg Turbuhaler®
SAMA
SALBUTAM OL + IPRATROPIU M Duolin
Atrovent®
DO
WNLOAD AT: asthmafoundati on.org.nz
CONTROLLERS
$
125 mcg 250 mcg Aerosol inhaler
Symbicort®
asthmaand respiratory .org.nz
Combination SABA +
IPRATROPIU M
$
Pulmicort®
$ 50 mcg
Funded
Short-Acting Muscarinic Antagonists (SAMA)
Bricanyl®
$
100 mcg Aerosol inhaler
Flixotide®
$
(SABA)
TERBUTALIN E
Ventolin®
$
+ PREVENTER
SALBUTAM OL
SalAir®
inhaler
FLUTICASO NE propionate
100/6
CATION
Short-Acting Beta2 Agonists
®
$ 200/6 Dry powder
®
SYMPTOM
100/6 200/6 Turbuhaler
DuoResp Spiromax
$
LONG-ACTING
$
CONTROLLER
(AIR) Therapy
BUDESONI DE + FORMOTER OL
Symbicort®
PREVENTERS
INHALER DEV
Anti-Inflam matory Reliever
NEW!
UPDATED INHALER IDENTIFICATION CHART INSIDE
Contents
Our Team
B E T T E R B R E AT H I N G S P R I N G 2 0 2 5
Chief Executive Letitia Harding
03 Letitia's Message
Deputy Chief Executive, Education & Development Manager Joanna Turner
05 Callum Massey's Story 06 Cough It Up Wrap-Up 09 Spring Allergies 10 Kath Cross: A Hero in Motion
Individual Giving Fundraising Executive Michaela Tahere PR & Comms Marketing Manager Chloe Bradwell
14 New Inhaler Chart
Digital Marketing Specialist Sam Treseder
15 Jade Stevens' Story
Digital Content & Marketing Advisor Jared McOnie
16 World COPD Day 17
An Eye on Osteoporosis
18 New Zealand Respiratory Conference 2025
You can also read this magazine online. Just head to issuu.com/betterbreathing Please recycle this material after use. This material has been printed with vegetable oil-based/mineral-free inks. The paper used comes from sustainable forests.
Thank you to our Friends of the Foundation partners for supporting our ongoing initiatives.
Māori Community Liaison, Youth Vaping Educator Sharon Pihema Community Liaison, Youth Vaping Educator Penelope Joyce Corporate Sponsorship & Engagement Advisor Paul Aschenberger Medical Director Prof. Bob Hancox, BSc, MB CHb, MRCP, MD, FRACP Chief Cultural Advisor – Māori Sir John Clarke, KNZM, CNZM
G O L D PA R T N E R S
S I LV E R PA R T N E R S
B R O N Z E PA R T N E R S
Level 2, 85 The Terrace Wellington 6011 PO Box 1459, Wellington 6140 Thank you to Pub Charity Ltd. for their continued support of the Foundation, allowing us to provide Better Breathing magazine free of charge to the respiratory and healthcare communities.
ph: 0800 100 506 asthmafoundation.org.nz asthmaandrespiratoryfoundation
FOREWORD
LETITIA'S MESSAGE WELL, IT IS NICE to see some sun coming through, and the days a little longer after quite a cold and wet winter across the country. As always, the team at the Foundation have been working hard on all sorts of activities, education, awareness campaigns, and advocacy. This year, instead of Breathe Better September, we decided to create the ‘Cough It Up’ campaign. This campaign was a new way to raise money and awareness of respiratory illnesses by hosting a range of auctions on Trade Me. It was generously supported by new and existing sponsors who freely donated goods and services. We would like to thank King Living, Deano Yipadee, Jolly Billboards, LEGO, Charlie Mollard, The Sleep Store, Olivia Wakefield Photography, Beko, Appliances Online, Good Fortune, Flight Coffee, Peoples Coffee, Emporio Coffee, and Mojo for these great items. Our Friends of the Foundation Sponsorship programme goes from strength to strength. It was in June that we heard the good news from the government that they will be supporting the installation of wool carpets in Kāinga Ora homes. The Foundation offered our support for this initiative, and we would like to acknowledge our Gold Sponsors, Wools of NZ, who we know also welcomed the news. Using wool will benefit so many people, and will create safer, healthier and more sustainable living environments for families.
Foundation's sister charity, The Heart of Aotearoa – Kia Manawanui Trust. You will have the opportunity to learn more about the Trust in the summer edition of the magazine in December – watch this space! Heart and lung health have a huge overlap across a wide range of diseases, especially in COPD. In fact, people with COPD are at increased risk of ischaemic heart disease and cardiac failure because of the shared risk factors of age and smoking status. If you have COPD or a loved one has it, then it might be good to join the live broadcast of the Big Baton Pass on World COPD Day (Wednesday 19 November). You can find out more about this on page 16. We will also be releasing the updated New Zealand COPD Guidelines at the New Zealand Respiratory Conference at the end of October. The lead author and the Foundation’s Medical Director, Professor Bob Hancox, will be presenting these. I would also like to thank Joanna Turner, the Foundation’s Education and Development Manager, who is one of the co-authors of the guidelines. Joanna has worked hard to bring everyone together to write these national guidelines, and that is no easy feat!
to youth vaping education has now trained 50 educators, made up of health professionals, school educators and community leaders from around the country. The educational tools provided in this course will help these trainers to inform and empower rangatahi and young people within their community. The one-day course is designed for anyone engaging with young people and their whānau about vaping harms. While primarily delivered in schools, it is also suited for community settings to ensure widespread awareness. Please contact Sharon Pihema if you want to know more at sharon@arfnz.org.nz
Our Friends of the Foundation programme isn’t just about sponsorship for the Foundation; it’s about partnering with companies that align with our core values to improve respiratory outcomes for all. So, if you are an organisation that wishes to support us, then please contact Paul Aschenberger at friends@arfnz.org.nz.
Joanna has also facilitated the update of the Inhaler Device Identification chart. The chart provides information on what asthma and COPD inhalers are available in New Zealand and if they are funded (fully or partially). The new update also includes the carbon footprint of each inhaler. A high carbon footprint inhaler is symbolised by a red footprint, while a low carbon inhaler is symbolised by a green footprint. The update is designed to empower patients and health professionals with further tools to make informed decisions. You can view the updated chart on page 14.
Of course, this message wouldn’t be complete without acknowledging the generous support of our readers, our community funding groups, our donor family, our Friends of the Foundation partners and New Zealanders who share our goal of improving respiratory health in Aotearoa. Thank you for all your support, and we look forward to updating you in December with a very special magazine update.
In addition to it being a busy time for the Foundation, it has also been an incredibly active time for the
Now, finally, a bit of an update on our vaping education mahi. The Train the Trainers (TTT) programme dedicated
Letitia Harding
Noho ora mai,
Asthma and Respiratory Foundation NZ Chief Executive
Better Breathing 3
Experience the natural attributes of wool: a fibre that's good for your health, the planet, and built to endure For a more comfortable home For a healthier living space For the earth and ocean For the style lovers For a safer home
For Life woolsnz.com
4 Better Breathing
CALLUM MASSEY'S STORY
RUNNING WITH PURPOSE: ONE ATHLETE’S MISSION TO INSPIRE OTHERS WHEN THE WHISTLE BLEW on his football season, goalkeeper Callum Massey had more than just goals on his mind.
“When I was younger, my asthma meant hospital visits, sleepless nights, and missed school and sporting events,” he says.
For every ball that got past him, he promised to run a kilometre for himself and for others living with asthma – a condition he has managed since childhood.
“The house I lived in didn’t have insulation, which made it even harder.
On Saturday 13 September, the 23-year-old from the North Shore completed a 21km run from Silo Park in Wynyard Quarter, raising almost $1400 for the Asthma and Respiratory Foundation NZ.
Over the years, careful management with his doctors has helped, and while he still experiences flare-ups – especially when sick – running has become an important outlet.
Callum – who plays for Metro FC’s Under-23 and First Team squads – knows first hand how challenging it can be to grow up struggling to breathe.
"My own struggles were tough, but I know many people face much worse.”
What started as a hobby quickly grew into a passion, with Callum now regularly completing half and full marathons. But he wanted to ensure this run was more meaningful, he says. “Being asthmatic myself, I wanted to show it’s possible to keep doing the things you love – and at the same time help others living with asthma and respiratory conditions.” Callum’s 21 km route was made up of 6 km loops around Auckland's Wynyard Quarter, with the final stretch bringing him to the finish line back at Silo Park. Foundation Chief Executive Letitia Harding says we are so grateful to Callum for turning his personal challenge into something that will inspire and support others. “His determination shows that even with asthma, you can push boundaries and achieve incredible things.”
"My own struggles were tough, but I know many people face much worse."
Better Breathing 5
$4858 RAISED! Who knew bidding could feel this good? The Cough It Up campaign has officially wrapped, and what a success it was! Aotearoa came together to support the 1 in 5 Kiwis living with respiratory disease, proving that community spirit – and a little friendly bidding – can go a long way. Over the course of the campaign, local businesses generously donated a variety of auction items, from LEGO
sets and coffee treats to a laundry room fit-out. Each week, these items were auctioned on Trade Me, giving participants the chance to snag something special while supporting a vital cause. The response was incredible, with Kiwis nationwide joining in to make a difference. Thanks to everyone who placed bids, donated, shared posts, and got involved. Every dollar will go directly to Te Hā Ora, the Asthma and Respiratory Foundation, helping to improve respiratory health, reduce hospitalisations, and fund essential education, advocacy, and research.
Beyond the funds raised, Cough It Up showcased the power of community and the generosity of Aotearoa. It was a fun, engaging, and meaningful way to support an important cause – reminding us all that small actions can make a big impact. A huge thank you to everyone involved – you helped turn a simple idea into a nationwide celebration of giving, awareness, and care for those living with respiratory disease.
Thanks to our amazing supporters who made this possible:
DEANO YIPADEE 6 Better Breathing
CHARLIE MOLLARD
The Big Billboard Takeover (Because Size Does Matter) The Kids Edition: Luxe Sofa Session with Nee Naw
Supported by JOLLY BILLBOARDS
Supported by KING LIVING and DEANO YIPADEE
The Newborn Baby Starter Pack (Sleep Not Guaranteed) Ye Olde Medieval Town Square LEGO Experience
Supported by THE SLEEP STORE
and OLIVIA WAKEFIELD PHOTOGRAPHY
Supported by LEGO
The “I Swear I’ll Do The Washing” Package The Coffee Snob Variety Starter Pack (Contains Caffeine)
Supported by BEKO and APPLIANCES ONLINE
Supported by BEKO, APPLIANCES ONLINE,
GOOD FORTUNE, FLIGHT COFFEE, PEOPLE'S COFFEE, EMPORIO COFFEE and MOJO
Better Breathing 7
Friends look out for each other. Become a Friends of the Foundation partner today, and align your business with New Zealand’s trusted voice for all respiratory health.
Interested in becoming a partner? Let’s chat about how your business can get involved, and in doing so, improve the lives of the 1 million Kiwi living with a respiratory condition. Head to our website asthmafoundation.org.nz or scan the QR code below for more info.
SPRING ALLERGIES
UNSETTLED SPRING WEATHER LIKELY TO SPARK ASTHMA AND ALLERGY FLARE-UPS SPRING HAS SPRUNG, and with it comes the annual surge in sneezing, wheezing, and asthma flare-ups as unsettled weather drives pollen into the air. This year’s season is already proving unsettled, with strong winds and fluctuating temperatures stirring up allergens – and more change is on the way. Foundation Chief Executive Letitia Harding says these shifting conditions make spring one of the hardest times of year for people with respiratory conditions. “Pollen loves warm, dry weather, and when the wind picks up, it gets everywhere, which is why this time of year can be so tough for people with respiratory conditions." "For people with asthma and allergies, that can quickly trigger symptoms.” It is important for asthma patients to ensure their medication is up to date – and is always on hand, she says.
“Being prepared and taking some simple steps can make all the difference.” Earth Sciences NZ principal scientist Chris Brandolino says this spring will be a season of two halves – typical of La Niña weather conditions. “The first part will be a bit like a teenager – lots of mood swings and ups and downs. “We’ll see plenty of windy days, and a blend of cooler and warmer-than-usual days, and a fair bit of rain,” he says. “But the second part of spring will pivot and bring more settled weather across the country.” La Niña will bring high pressure, which Brandolino calls “happy weather” in the second half of spring – less wind and rain, more sunshine, and warmer temperatures. Up to 80% of asthma is associated with allergies, with one in eight adults and one in eight children in New Zealand affected.
Top tips for the spring allergy season: • Avoid going outside when the pollen count is very high (midday is usually peak) • Keep windows closed – at home and in the car – to avoid pollen coming inside with the breeze • Dry your clothes indoors because pollen will stick to them if they are outside • Invest in an air purifier with a HEPA (High-Efficiency Particulate Air) filter • Keep your medication at hand in case of an emergency • Do a spring clean using allergyfriendly products • Take a shower at night to wash the pollen off
Better Breathing 9
KATH CROSS COVER STORY
HER RIDE IS FAR FROM OVER
The inspirational story of a double-lung transplant receiver, and her admirable mission to spread awareness.
10 Better Breathing
Better Breathing 11
"I've been given a new life... it really is the ultimate gift."
Above: Kath in hospital for a double-lung transplant, October 2024. 12 Better Breathing
COVER STORY
KATH CROSS: A HERO IN MOTION SHE COULDN'T blow out the candles on her 50th birthday cake.
The next two and a half years were a downward spiral.
Now, with a stranger’s lungs in her chest, Kath Cross is gearing up to ride 30 kilometres in one of New Zealand’s toughest cycling events.
“I couldn’t walk to the letterbox without stopping for breath.”
The 51-year-old Rotorua woman will line up for the 30 km mountain bike ride at the Lake Taupō Cycle Challenge in November, just nine months after receiving a double-lung transplant. She’s doing it not just for herself, but to raise awareness and funds for the Asthma and Respiratory Foundation NZ. “I’ve been given a new life – it feels so surreal,” she says. “This ride is my way of giving back, and showing people what’s possible.” Kath lives with rheumatoid arthritisassociated obliterative bronchiolitis (RA-OB), a rare lung disease that mimics “popcorn lung.” Initially misdiagnosed as chronic obstructive pulmonary disease (COPD), she was prescribed inhalers and nebulisers that never worked. “Eventually, they did more tests and found my lung function was just 29%."
Doctors eventually told her she may have only a year to live and placed her on the active waitlist for a transplant. “I remember thinking, ‘This isn’t the end. I’ve got to keep going.’” Six months later, the call came. In October 2024, she became New Zealand lung transplant recipient #420. Seven weeks after her miracle surgery, she was home, and the very first thing she did was get back on her bike. “I biked 5 km. It felt amazing just to move again.” Mountain biking has long been her passion. During Covid lockdowns, she and her husband John rode together every day. “John’s been my rock through all of this. I couldn’t have done it without him.” For years, Kath kept her illness quiet. “I had oxygen tanks, but I wouldn’t
use them," she says. "I just wanted to be normal. I didn’t want anyone feeling sorry for me.” Now she’s speaking out, determined to highlight the impact of respiratory disease in New Zealand. This year, she’s already planning a symbolic milestone – on the first anniversary of her transplant, she will climb Mount Maunganui. And for her 52nd birthday, she has one request: “I want as many candles on the cake as possible. This time, I’m going to blow them all out.” She doesn’t know much about her donor – only that she was a 61-year-old woman – but she plans to write to the family on the one-year mark. “I want them to know I’m living the best life I can. It really is the ultimate gift.” Her lung function is now at 72%, and she’s hoping to get to 100% – or close to. When she takes to the Taupō trails this November, Kath won’t just be racing – she’ll be celebrating survival, resilience, and the breath that allows her to ride again.
Want to support Kath taking on the Taupō cycle challenge? Scan the QR code below to make a donation.
Better Breathing 13
INHALER DEVICE IDENTIFICATION
$
$
SalAir®
Ventolin®
$
$
$
100/6 200/6 Turbuhaler®
200/6 Dry powder inhaler
TERBUTALINE
IPRATROPIUM
Duolin HFA®
Bricanyl®
Atrovent
$
100 mcg Aerosol inhaler
SALBUTAMOL + IPRATROPIUM
®
$
$
100 mcg/20 mcg Aerosol inhaler
20 mcg Aerosol inhaler
250 mcg Turbuhaler®
Inhaled Corticosteroids (ICS) FLUTICASONE propionate
BUDESONIDE
Flixotide®
$
$
$
$
50 mcg 125 mcg 250 mcg Aerosol inhaler
50 mcg
100 mcg Accuhaler®
250 mcg
$
$ 100 mcg
Combination Inhaled Corticosteroids (ICS) + Long-Acting Beta2 Agonists (LABA) BUDESONIDE + FORMOTEROL
Symbicort®
$ 100/6
DuoResp Spiromax®
$
$
$
$
200/6 400/12* Turbuhaler®
200/6 400/12* Dry powder inhaler
Vannair®
$
$
100/6 200/6 Aerosol inhaler
*Symbicort 400/12 and DuoResp Spiromax 400/12 only funded if no more than 2 doses per day Note: Symbicort 100/6, 200/6 and DuoResp Spiromax 200/6 are currently approved for Anti-Inflammatory Reliever (AIR) therapy. Vannair 100/6 and 200/6 is approved for maintenance use, but its use in AIR therapy is an unapproved indication.
FORMOTEROL (eformoterol)
Serevent®
Oxis
®
$
$
200 mcg Turbuhaler®
25 mcg Aerosol inhaler
50 mcg Accuhaler®
6 mcg Turbuhaler®
INDACATEROL
Onbrez Breezhaler®
UMECLIDINIUM + VILANTEROL
Spiolto Respimat
Anoro Ellipta
®
®
Combination Inhaled Corticosteroids (ICS) + Long-Acting Beta2 Agonists (LABA) FLUTICASONE propionate + SALMETEROL
$
$
®
®
50 mcg/110 mcg Breezhaler®
Spacers are available free to those who need them on a Practitioners Supply Order (PSO). Contact Manatū Hauora Ministry of Health for an order form on 0800 353 2425. Everyone should have an action plan. Find a range of management plans at asthmafoundation.org.nz
Funded
$
$
Funded by endorsement
$
Not funded
Low carbon footprint1
$
Partially funded
Funded by Special Authority
High carbon footprint1
14 Better Breathing
$
100/50* 250/50* Accuhaler®
*100/50 and 250/50 accuhaler only funded if no more than 2 doses per day
TIOTROPIUM
Spiriva®
Spiriva Respimat®
$ 2.5 mcg Fine mist inhaler
$ 100/25
$ 200/25
Dry powder inhaler
UMECLIDINIUM
Incruse Ellipta®
GLYCOPYRRONIUM
Seebri® Breezhaler®
$ 62.5 mcg Dry powder inhaler
$ 50 mcg Breezhaler®
Combination Inhaled Corticosteroids (ICS) + Long-Acting Muscarinic Antagonist (LAMA) + Long-Acting Beta2 Agonist (LABA)
Trelegy Ellipta®
$
Funded via Special Authority: LAMA + LABA inhaler is subsidised only for patients who have been stabilised on a LAMA and the prescriber considers that the patient would receive additional benefit from switching to a combination product. Not subsidised if patient is also receiving treatment with a combination ICS and LABA.
$
Breo Ellipta®
$
$
50/25 125/25 250/25 Aerosol inhaler
18 mcg Handihaler®
Ultibro Breezhaler
62.5 mcg/25 mcg Dry powder inhaler
FLUTICASONE furoate + VILANTEROL
Seretide®
Funded by endorsement: LAMA inhaler is subsidised only for patients who have been diagnosed as having COPD using spirometry if spirometry is possible, and the prescription is endorsed accordingly (i.e. COPD documented as indication on prescription). Not subsidised if patient is also receiving treatment with another susidised LAMA.
GLYCOPYRRONIUM + INDACATEROL
$
2.5 mcg/2.5 mcg Fine mist inhaler
50 mcg 100 mcg
Note: Beclazone® and Qvar® are not dose equivalent and are not interchangeable.
FLUTICASONE furoate + UMECLIDINIUM + VILANTEROL $
$
$
50 mcg 100 mcg 250 mcg Aerosol inhalers
400 mcg
$
150 mcg 300 mcg Breezhaler®
Combination Long-Acting Muscarinic Antagonists (LAMA) + Long-Acting Beta2 Agonists (LABA) TIOTROPIUM + OLODATEROL
$
Long-Acting Muscarinic Antagonists (LAMA)
$
$
$
$
$
Long-Acting Beta2 Agonists (LABA) SALMETEROL
Qvar® (ultrafine particle) $
RELIEVER + PREVENTER
$
BECLOMETHASONE dipropionate
Beclazone®
Pulmicort®
RELIEVERS
SALBUTAMOL
DuoResp Spiromax®
Combination SABA + SAMA
$ 100 mcg/62.5 mcg/25 mcg Dry powder inhaler
BUDESONIDE + GLYCOPYRRONIUM + FORMOTEROL
Breztri Aerosphere®
$ 160 mcg/7.2 mcg/5 mcg Aerosol inhaler
Funded via Special Authority: ICS + LAMA + LABA ‘triple therapy’ inhaler is subsidised only for patients with a diagnosis of COPD confirmed by spirometry, or spirometry has been attempted and technically acceptable results are not possible and the patient is currently on an ICS/LABA or a LAMA/LABA, and meets the following clinical criteria: • Patient has a COPD Assessment Test (CAT) score greater than 10, or • Patient has had 2 or more exacerbations in the previous 12 months, or • Patient has had one exacerbation requiring hospitalisation in the previous 12 months, or • Patient has had an eosinophil count greater than or equal to 0.3 x 10^9 cells/L in the previous 12 months or the patient is currently receiving multiple inhaler triple therapy (ICS/LAMA/LABA) and met at least one of the clinical criteria above prior to starting multiple inhaler triple therapy.
Funding information updated as of 1 June 2025.
Visit www.pharmac.govt.nz
1. Wurzel DF, Montgomery BD, Anderson N et al. Environmental impact of inhaled medicines: A Thoracic Society of Australia and New Zealand position statement. Respirology, 2025.
D O W N L O A D AT:
asthmafoundation.org.nz
CONTROLLER + PREVENTER
BUDESONIDE + FORMOTEROL
Symbicort®
Short-Acting Muscarinic Antagonists (SAMA)
PREVENTERS
Short-Acting Beta2 Agonists (SABA)
LONG-ACTING SYMPTOM CONTROLLERS (FOR COPD)
Anti-Inflammatory Reliever (AIR) Therapy
asthmaandrespiratory.org.nz
JADE STEVENS' STORY
"PLEASE DON'T DIE TODAY..." — A MOTHER’S FIGHT AGAINST ASTHMA "I LOVE YOU, MUMMY. Please don’t die today." That’s what Jade Stevens’ five-year-old son whispered to her one morning before school. For Jade, a mother-of-three from Wellington, those words captured the fear that comes with living – and parenting – while battling asthma. Jade was diagnosed in her late 20s with brittle asthma – a rare and severe form of the disease, more commonly referred to now as severe or difficultto-control asthma. At the time, she was being admitted to the hospital nearly every month, with long stays in intensive care and repeated courses of oral steroids. All this while raising three young boys.
one day. He was just five. He kissed me goodbye, paused, and whispered, ‘I love you, Mummy. Please don’t die today.’ "I reassured him, but inside I was breaking. That fear – his and mine – was all too real." Today, thanks to a biological treatment, Jade's condition is under control and her symptoms are manageable. "The treatment gave me my life back. "The hospital visits have become rare, and I’ve finally been able to stop taking steroids."
reality of asthma that many New Zealanders are still unaware of. "Jade’s experience is a reminder that asthma can affect people in very different ways, and for some, it’s far more serious than many realise.” In New Zealand, asthma affects 1 in 8 adults and children, kills an average of 96 people each year, and is responsible for the hospitalisations of thousands of children - many of whom will have had a potentially life-threatening asthma attack.
Her children are now teenagers and she’s able to be the mum she always wanted to be at the beginning, she says.
"I wanted to be the kind of mum who could be there for everything - every school pickup, every bedtime story but instead, hospital beds replaced family dinners.
"I can go to my eldest son’s band Intercite gigs, school events, quad bike adventures, or just sit on the couch and watch a movie without them having to worry that Mum might be going to hospital again."
"I’ll never forget the moment I dropped my youngest off at school
Foundation NZ Chief Executive Letitia Harding says Jade’s story shows the
Better Breathing 15
WORLD COPD DAY 19 November
BE PART OF A global movement to raise awareness of chronic obstructive pulmonary disease (COPD) and celebrate the benefits of physical activity for lung health. Join the live broadcast of the Big Baton Pass this World COPD Day – Wednesday 19 November 2025. Like an Olympic Torch relay, the baton will be “passed” virtually across the globe – starting in New Zealand and finishing on the US west coast – with stories, interviews and health information to help people with COPD. The event will start in New Zealand at 10am. You will hear from the following speakers: • Joanna Turner (Asthma and Respiratory Foundation NZ) will share various COPD resources for patients and health professionals • Sarah Candy (Pulmonary Rehabilitation Coordinator) will talk about the Better Breathing Programme – an 8-week programme designed for people with long-term respiratory conditions • Mersha Shepherd (Community Respiratory Specialist) will discuss community exercise programmes
16 Better Breathing
Following the New Zealand presentations, you will hear from other speakers in Australia and around the world. Topics covered will include the role of different healthcare professionals in pulmonary rehabilitation (PR), how to ask for a referral to PR, how to incorporate yarning circles, hydrotherapy, how to exercise in a changing climate, how to break up sedentary behaviour, how to use wearables and what the metrics mean, how to be active in the home, what spirometry is, and how is it done.
If you are interested in joining the Big Baton Pass, simply head to copdbatonpass.org or scan the QR code below on the day.
HEALTH PROFESSIONAL
AN EYE ON OSTEOPOROSIS OSTEOPOROSIS, translated as 'porous bone', is a medical condition affecting your bones. People with osteoporosis have bones that are weaker and more likely to get broken (fractured). Often, they don’t know they have the condition until they have a knock or fall that results in a break. Wrist, hip and spine bones are most commonly affected. Spinal fractures cause the bones in the spine to get squashed (rather than break apart). They are less obvious than other fractures and can result in pain, loss of height and a more curved spine. People with chronic obstructive pulmonary disease (COPD) are more likely to develop osteoporosis. This is because some of the risk factors for osteoporosis can also be associated with COPD. Things like smoking, low body weight, older age, physical inactivity, prednisone use, and inflammation.
Osteoporosis NZ osteoporosis.org.nz
If you have COPD, it is useful to be aware of osteoporosis and consider talking to you GP about osteoporosis screening. Osteoporosis New Zealand and the Royal Osteoporosis Society are two organisations with useful information about osteoporosis. Both of their websites also have a simple online screening tool, which you can use to check your own bone health. The Royal Osteoporosis Society promote “strong, steady and straight” physical activity and exercise for people with osteoporosis.
The Royal Osteoporosis Society theros.org.uk
“Strong” exercises are designed to build bone and muscle strength. They include weight-bearing activities like walking, jogging and dancing along with resistance exercises using weights, resistance bands or body weight.
Pilates are good activities, as well as learning techniques for safe lifting and bending. Check out their websites for more details on this programme. The main thing to remember is that physical activity is an important part of osteoporosis treatment and should not be avoided.
About the author Zöe Manderson is a respiratory physiotherapist in Taranaki for Te Whatu Ora and a member of the Asthma and Respiratory Foundation NZ's Scientific Advisory Board.
“Steady” exercises aim to improve balance and reduce the risk of falls. Anything that challenges your balance can be useful or specific activities like yoga and Tai Chi. “Straight” exercises involve back muscle strengthening to reduce pain and improve posture. Swimming and Better Breathing 17
2
DAYS
20
SPEAKERS
EXHIBITORS
NZRC2025.CO.NZ 18 Better Breathing
10
THANK YOU TO OUR GENEROUS NZRC 2025 SPONSORS Principal Sponsor
Gold Sponsor
Supported by grant funding from
Leading sustainable respiratory care in New Zealand
As leaders in respiratory medicine, we are committed to reduce the carbon footprint of our medicines across the entire supply chain. At AstraZeneca Australia and New Zealand, we have been working to deliver life-changing medicines to patients for more than 60 years. AstraZeneca is a global, science-led biopharmaceutical company engaged in the research, development, manufacture and supply of medicines that aim to make a real difference to the lives of New Zealanders. Our areas of focus include:
Oncology
Cardiovascular, Renal & Metabolism
Respiratory & Immunology
Rare Disease
Registered user AstraZeneca Limited, PO Box 87453, Meadowbank, Auckland 1742. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 0800 684 432 or (09) 306 5650 or via https://contactazmedical.astrazeneca.com. NZ-2954.